Vimta Labs (524394) Q1 24/25 earnings summary

Executive summary

• Q1 FY25 began with stable business performance, with total income reaching Rs. 824 million and EBITDA at Rs. 252 million, maintaining a 30.6% margin.

• PAT for Q1 FY25 was Rs. 123 million, with a PAT margin of 14.9% and basic EPS of Rs. 5.5.

• The Board reviewed and approved unaudited financial results on July 17, 2024, with unmodified limited review reports.

• The company maintains a strong cash position with Rs. 324 million in cash and cash equivalents as of June 30, 2024.

• CapEx for Q1 FY25 was Rs. 164 million, supporting ongoing expansion and operational improvements.

Financial highlights

• Q1 FY25 consolidated revenue from operations was Rs. 817.55 million, down from Rs. 834.85 million in Q1 FY24.

• EBITDA for Q1 FY25 was Rs. 252.1 million, nearly flat year-over-year, with EBITDA margin at 30.6%.

• PAT increased 0.7% year-over-year to Rs. 123 million, with a PAT margin of 14.9%.

• Cash and equivalents stood at Rs. 324 million; total borrowing at Rs. 120 million, with a debt-to-equity ratio of 0.04x.

• CapEx for the quarter was Rs. 164 million.

Outlook and guidance

• Management expects a step-up in revenue from Q2 FY25 as new capacity comes online, targeting Rs. 950-1,000 million quarterly revenue by Q4 FY25.

• Ambition to reach Rs. 5,000 million annual revenue by FY26, with the new facility supporting this growth.

• Initial utilization of new capacity expected at 20-30% in the first year, ramping up thereafter.

• Growth strategies focus on market penetration, operational excellence, and leveraging technology.

• The proposed amalgamation of EMTAC Laboratories Private Limited is underway, with NCLT granting exemption from holding meetings.